Effect of discontinuing immune-modulating drugs versus control group on prognosis in patients with relapsing-remitting multiple sclerosis

Effect of discontinuing immune-modulating drugs versus control group on prognosis in patients with relapsing-remitting multiple sclerosis: a single-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N516

Enrollment

178

Registered

2024-06-17

Start date

2024-07-05

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Routine treatment of multiple sclerosis with the same dose that the patient has already received, plus stopping any immunosuppressive drugs (including dimethyl fuma

Eligibility

Sex/Gender

All

Age

55 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 55 to 80 years Relapsing-remitting multiple sclerosis Taking drugs that modulate the immune system

Exclusion criteria

Exclusion criteria: Disease attack in the last 5 years Taking Tysabri or Fingolimod drugs

Design outcomes

Primary

Measure	Time frame
Average disease severity. Timepoint: Before the intervention and 24 months later. Method of measurement: Based on the Extended Disability Status Scale (EDSS).;Mean number of gadolinium-enhancing lesions. Timepoint: Before intervention and 24 months after. Method of measurement: Using MRI imaging.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sajad Daneshyar

Hamedan University of Medical Sciences

s.danshyar72@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026